BR112023018530A2 - Conjugado de ação prolongada, composição farmacêutica e seu uso - Google Patents

Conjugado de ação prolongada, composição farmacêutica e seu uso

Info

Publication number
BR112023018530A2
BR112023018530A2 BR112023018530A BR112023018530A BR112023018530A2 BR 112023018530 A2 BR112023018530 A2 BR 112023018530A2 BR 112023018530 A BR112023018530 A BR 112023018530A BR 112023018530 A BR112023018530 A BR 112023018530A BR 112023018530 A2 BR112023018530 A2 BR 112023018530A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
long action
conjugate
long
action conjugate
Prior art date
Application number
BR112023018530A
Other languages
English (en)
Inventor
Ram Lee A
Hyeon PARK Da
Lim Oh Euh
Young Kim Jin
Sub Park Jun
Yun Kim Sang
Ho Heo Yong
Yon KIM Yu
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of BR112023018530A2 publication Critical patent/BR112023018530A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

conjugado de ação prolongada, composição farmacêutica e seu uso. a presente invenção se refere a um conjugado de ação prolongada de um análogo de interleucina-2 com afinidade de ligação alterada para receptores de interleucina-2.
BR112023018530A 2021-03-31 2022-03-31 Conjugado de ação prolongada, composição farmacêutica e seu uso BR112023018530A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20210042305 2021-03-31
PCT/KR2022/004620 WO2022211537A1 (ko) 2021-03-31 2022-03-31 신규한 면역 활성 인터루킨 2 아날로그 결합체 및 이의 제조 방법

Publications (1)

Publication Number Publication Date
BR112023018530A2 true BR112023018530A2 (pt) 2023-10-10

Family

ID=83459706

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023018530A BR112023018530A2 (pt) 2021-03-31 2022-03-31 Conjugado de ação prolongada, composição farmacêutica e seu uso

Country Status (13)

Country Link
US (1) US20240009317A1 (pt)
EP (1) EP4316528A1 (pt)
JP (1) JP2024512418A (pt)
CN (1) CN116916969A (pt)
AR (1) AR125263A1 (pt)
AU (1) AU2022209248B2 (pt)
BR (1) BR112023018530A2 (pt)
CA (1) CA3205058C (pt)
CL (1) CL2023002504A1 (pt)
IL (1) IL304365A (pt)
MX (1) MX2023010926A (pt)
TW (1) TW202304521A (pt)
WO (1) WO2022211537A1 (pt)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
KR100507796B1 (ko) * 2003-04-03 2005-08-17 한미약품 주식회사 생체내 반감기가 증가된 ｐｅｇ-생리활성 폴리펩티드 동종이량체 결합체 및 이의 제조방법
IL289475B2 (en) * 2014-07-21 2023-10-01 Delinia Inc Molecules that activate T cells are selectively regulated for the treatment of autoimmune diseases
TWI683667B (zh) 2014-10-21 2020-02-01 開曼群島商賽生製藥國際有限公司 用免疫刺激物治療癌症
CN109071623B (zh) * 2016-05-04 2022-05-27 美国安进公司 用于扩增t调节性细胞的白细胞介素-2突变蛋白
SG11201903882VA (en) * 2016-11-08 2019-05-30 Delinia Inc Il-2 variants for the treatment of autoimmune diseases
KR20200086722A (ko) * 2017-11-21 2020-07-17 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 인터루킨-2의 부분 효능제
TWI791894B (zh) * 2018-09-21 2023-02-11 大陸商信達生物製藥（蘇州）有限公司 新型白介素２及其用途
US20220025007A1 (en) * 2018-12-21 2022-01-27 Hanmi Pharm. Co., Ltd. Novel immunosuppressive interleukin 2
US20230002466A1 (en) * 2019-08-13 2023-01-05 Elpis Biopharmaceuticals Engineered interleukin-2 receptor beta agonists

Also Published As

Publication number Publication date
US20240009317A1 (en) 2024-01-11
IL304365A (en) 2023-09-01
AR125263A1 (es) 2023-06-28
KR20220136285A (ko) 2022-10-07
TW202304521A (zh) 2023-02-01
CN116916969A (zh) 2023-10-20
EP4316528A1 (en) 2024-02-07
AU2022209248A1 (en) 2022-10-20
JP2024512418A (ja) 2024-03-19
MX2023010926A (es) 2023-09-27
CA3205058A1 (en) 2022-10-26
AU2022209248B2 (en) 2023-06-29
WO2022211537A1 (ko) 2022-10-06
CL2023002504A1 (es) 2024-01-26
CA3205058C (en) 2024-04-09

Similar Documents

Publication Publication Date Title
BR112021017408A2 (pt) Compostos tricíclicos fundidos úteis como agentes anticancerosos
ECSP19000282A (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco
BR112018075653A2 (pt) anticorpos anti-b7-h3 e conjugados anticorpo fármaco
BR112018075630A2 (pt) anticorpos anti-cd98 e conjugados de fármaco de anticorpo
BR112018075644A2 (pt) anticorpos anti-cd98 e conjugados de anticorpo e fármaco
BR112019005637A2 (pt) análogos da insulina com afinidade reduzida para o receptor de insulina e seu uso
CL2021001790A1 (es) Enlazadores sin trazas, conjugados de proteínas de los mismos y composiciones de los mismos
CO2022001210A2 (es) Conjugados de il-2 y métodos de uso para tratar enfermedades autoinmunes
CL2021003273A1 (es) Composición farmacéutica parenteral del agonista dual glp1/2
BR112022002496A2 (pt) Compostos deuterados para uso no tratamento de câncer
BR112022000854A2 (pt) Conjugados anticorpo - agonista de sting e seu uso em imunoterapia
BR112015010703A8 (pt) Uso de uma composição farmacêutica e composição farmacêutica
CL2021003266A1 (es) Anticuerpos de receptor de péptido natriurético 1 y métodos de uso
ECSP21074141A (es) Composición farmacéutica acuosa de anticuerpo anti-il17a y su uso
BR112023005789A2 (pt) Composição farmacêutica compreendendo conjugado anticorpo-fármaco e uso de composição farmacêutica
BR112022012410A2 (pt) Degradadores smarca e usos dos mesmos
CO2022002898A2 (es) Composiciones que comprenden tigolaner para el control de parásitos
BR112023001471A2 (pt) Composição farmacêutica de anticorpo anti-pd-1 e uso da mesma
CL2023001746A1 (es) Composición farmacéutica de agonistas duales de glp 1/glp 2
BR112023018530A2 (pt) Conjugado de ação prolongada, composição farmacêutica e seu uso
BR112023023223A2 (pt) Degradadores de cdk2 e usos dos mesmos
AR106981A1 (es) Una composición antimicrobiana
BR112022003046A2 (pt) Conjugados de il-15 e usos dos mesmos
CL2023001747A1 (es) Composición farmacéutica de agonistas duales de glp-1/glp-2
CL2023001745A1 (es) Composición farmacéutica de agonistas duales de glp-1/glp-2